

# Publikationsliste 2011

## Originalpublikationen

1. Achermann Y, Vogt M, Spormann C, Kolling C, Remschmidt C, Wust J, Simmen B, Trampuz A. Characteristics and outcome of 27 elbow periprosthetic joint infections: results from a 14-year cohort study of 358 elbow prostheses. *Clin Microbiol Infect* 2011;17(3):432-8.
2. Arenas-Pinto A, Grant A, Bhaskaran K, Copas A, Carr A, Worm SW, Martinez E, Reiss P, Dunn D, Weber R, Hoy J, Weller I. Risk factors for fatality in HIV-infected patients with dideoxynucleoside-induced severe hyperlactataemia or lactic acidosis. *Antivir Ther* 2011;16(2):219-26.
3. Audige A, Hofer U, Dittmer U, van den Broek M, Speck RF. Evaluation of the immunomodulatory and antiviral effects of the cytokine combination IFN-alpha and IL-7 in the lymphocytic choriomeningitis virus and Friend retrovirus mouse infection models. *Viral Immunol* 2011;24(5):375-85.
4. Baker JV, Neuhaus J, Duprez D, Kuller LH, Tracy R, Belloso WH, De Wit S, Drummond F, Lane HC, Ledergerber B, Lundgren J, Nixon DE, Paton NI, Neaton JD. Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection. *J Acquir Immune Defic Syndr* 2011;56(1):36-43.
5. Boillat Blanco N, Probst A, Da Costa VW, Giulieri S, Bernasconi E, Calmy A, Elzi L, Rauch A, Weber R, Bertisch B, Cavassini M, Bochud PY. Impact of a nurse vaccination program on hepatitis B immunity in a Swiss HIV clinic. *J Acquir Immune Defic Syndr* 2011;58(5):472-4.
6. Braun J, Held L, Ledergerber B. Predictive Cross-validation for the Choice of Linear Mixed-Effects Models with Application to Data from the Swiss HIV Cohort Study. *Biometrics* 2011. [Epub ahead of print]
7. Cain LE, Logan R, Robins JM, Sterne JA, Sabin C, Bansi L, Justice A, Goulet J, van Sighem A, de Wolf F, Bucher HC, von Wyl V, Esteve A, Casabona J, del Amo J, Moreno S, Seng R, Meyer L, Perez-Hoyos S, Muga R, Lodi S, Lanoy E, Costagliola D, Hernan MA. When to initiate combined antiretroviral therapy to reduce mortality and AIDSdefining illness in HIV-infected persons in developed countries: an observational study. *Ann Intern Med* 2011;154(8):509-15.
8. Coleman BL, Kuster SP, Gubbay J, Scheifele D, Li Y, Low D, Crowcroft N, Mazzulli T, Shi L, Halperin SA, Law B, McGeer A. Immunogenicity of a half-dose of adjuvanted 2009 pandemic H1N1 influenza vaccine in adults: a prospective cohort study. *Eur J Clin Microbiol Infect Dis* 2011. [Epub ahead of print]
9. Colombo C, Masserey V, Ruef C. Incidence of needlestick injuries and other sharps exposures in Swiss acute care hospitals: results of a sentinel surveillance study. *J Hosp Infect* 2011;77(2):181-3.

10. Cozzi-Lepri A, Paredes R, Phillips A, Clotet B, Kjaer J, Von Wyl V, Kronborg G, Castagna A, Bogner J, Lundgren J. The rate of accumulation of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance in patients kept on a virologically failing regimen containing an NNRTI(\*). *HIV Med* 2011. [Epub ahead of print]
11. di Iulio J, Ciuffi A, Fitzmaurice K, Kelleher D, Rotger M, Fellay J, Martinez R, Pulit S, Furrer H, Gunthard HF, Battegay M, Bernasconi E, Schmid P, Hirschel B, Barnes E, Klenerman P, Telenti A, Rauch A. Estimating the net contribution of interleukin-28B variation to spontaneous hepatitis C virus clearance. *Hepatology* 2011;53(5):1446-54.
12. El Amari EB, Combescure C, Yerly S, Calmy A, Kaiser L, Hasse B, Furrer H, Cavassini M, Vernazza P, Hirsch H, Bernasconi E, Hirschel B. Clinical relevance of cytomegalovirus viraemia. *HIV Med* 2011;12(7):394-402.
13. Elzi L, Steffen I, Furrer H, Fehr J, Cavassini M, Hirschel B, Hoffmann M, Bernasconi E, Bassetti S, Battegay M. Improved sensitivity of an interferon-gamma release assay (TSPOT. TB) in combination with tuberculin skin test for the diagnosis of latent tuberculosis in the presence of HIV co-infection. *BMC Infect Dis* 2011;11:319.
14. Fenner L, Gagneux S, Helbling P, Battegay M, Rieder HL, Pfyffer GE, Zwahlen M, Furrer H, Siegrist HH, Fehr J, Dolina M, Calmy A, Stucki D, Jatton K, Janssens JP, Stalder JM, Bodmer T, Ninet B, Bottger EC, Egger M. Mycobacterium tuberculosis Transmission in a Country with Low Tuberculosis Incidence: Role of Immigration and HIV Infection. *J Clin Microbiol* 2011 [Epub ahead of print].
15. Fehr J, Glass TR, Louvel S, Hamy F, Hirsch HH, von Wyl V, Boni J, Yerly S, Burgisser P, Cavassini M, Fux CA, Hirschel B, Vernazza P, Martinetti G, Bernasconi E, Gunthard HF, Battegay M, Bucher HC, Klimkait T. Replicative phenotyping adds value to genotypic resistance testing in heavily pre-treated HIV-infected individuals--the Swiss HIV Cohort Study. *J Transl Med* 2011;9:14.
16. Fux CA, Baumann S, Furrer H, Mueller NJ. Is lower serum 25-hydroxy vitamin D associated with efavirenz or the non-nucleoside reverse transcriptase inhibitor class? *AIDS* 2011;25(6):876-8.
17. Gianella S, von Wyl V, Fischer M, Niederoest B, Battegay M, Bernasconi E, Cavassini M, Rauch A, Hirschel B, Vernazza P, Weber R, Joos B, Gunthard HF. Effect of early antiretroviral therapy during primary HIV-1 infection on cell-associated HIV-1 DNA and plasma HIV-1 RNA. *Antivir Ther* 2011;16(4):535-45.
18. Gilomen S, Ruef C, Held L, Cathomas A, French LE, Hafner J. Successful control of methicillin-resistant *Staphylococcus aureus* outbreak at a university department of dermatology. *J Eur Acad Dermatol Venereol* 2011;25(4):441-6.
19. Giner AM, Kuster SP, Zbinden R, Ruef C, Ledergerber B, Weber R. Initial management of and outcome in patients with pneumococcal bacteremia: a retrospective study at a Swiss university hospital, 2003-2009. *Infection* 2011;39(6):519-26.

20. Haas A, Zimmermann K, Graw F, Slack E, Rusert P, Ledergerber B, Bossart W, Weber R, Thurnheer MC, Battegay M, Hirschel B, Vernazza P, Patuto N, Macpherson AJ, Gunthard HF, Oxenius A. Systemic antibody responses to gut commensal bacteria during chronic HIV-1 infection. *Gut* 2011;60(11):1506-19.
21. Hasse B, Ledergerber B, Furrer H, Battegay M, Hirschel B, Cavassini M, Bertisch B, Bernasconi E, Weber R. Morbidity and Aging in HIV-Infected Persons: The Swiss HIV Cohort Study. *Clin Infect Dis* 2011;53(11):1130-1139.
22. Herbeck JT, Muller V, Maust BS, Ledergerber B, Torti C, Di Giambenedetto S, Gras L, Gunthard HF, Jacobson LP, Mullins JI, Gottlieb GS. Is the virulence of HIV changing? A meta-analysis of trends in prognostic markers of HIV disease progression and transmission. *AIDS* 2011. [Epub ahead of print]
23. Hofmaenner, D; Kovari, H; Weber, A; Weishaupt, D; Speck, R F. Nodular regenerative hyperplasia of the liver associated with didanosine persists for years even after ist interruption. *BMJ Case Reports* 2011. [Epub ahead of print]
24. Huelsmann PM, Hofmann AD, Knoepfel SA, Popp J, Rauch P, Di Giallonardo F, Danke C, Gueckel E, Schambach A, Wolff H, Metzner KJ, Berens C. A suicide gene approach using the human pro-apoptotic protein tBid inhibits HIV-1 replication. *BMC Biotechnol* 2011;11:4.
25. Kaufmann GR, Elzi L, Weber R, Furrer H, Giulieri S, Vernazza P, Bernasconi E, Hirschel B, Battegay M. Interruptions of cART limits CD4 T-cell recovery and increases the risk for opportunistic complications and death. *AIDS* 2011;25(4):441-51.
26. Keiser O, Spycher B, Rauch A, Calmy A, Cavassini M, Glass TR, Nicca D, Ledergerber B, Egger M. Outcomes of Antiretroviral Therapy in the Swiss HIV Cohort Study: Latent Class Analysis. *AIDS Behav* 2011. [Epub ahead of print]
27. Kenfak-Foguena A, Schoni-Affolter F, Burgisser P, Witteck A, Darling KE, Kovari H, Kaiser L, Evison JM, Elzi L, Gurter-De La Fuente V, Jost J, Moradpour D, Abravanel F, Izpopet J, Cavassini M. Hepatitis E Virus seroprevalence and chronic infections in patients with HIV, Switzerland. *Emerg Infect Dis* 2011;17(6):1074-8.
28. Knoepfel SA, Di Giallonardo F, Daumer M, Thielen A, Metzner KJ. In-depth analysis of Gto- A hypermutation rate in HIV-1 env DNA induced by endogenous APOBEC3 proteins using massively parallel sequencing. *J Virol Methods* 2011;171(2):329-38.
29. Kouyos RD, von Wyl V, Hinkley T, Petropoulos CJ, Haddad M, Whitcomb JM, Boni J, Yerly S, Cellerai C, Klimkait T, Gunthard HF, Bonhoeffer S. Assessing Predicted HIV-1 Replicative Capacity in a Clinical Setting. *PLoS Pathog* 2011;7(11):e1002321.
30. Kouyos RD, von Wyl V, Yerly S, Boni J, Rieder P, Joos B, Taffe P, Shah C, Burgisser P, Klimkait T, Weber R, Hirschel B, Cavassini M, Rauch A, Battegay M, Vernazza PL, Bernasconi E, Ledergerber B, Bonhoeffer S, Gunthard HF. Ambiguous nucleotide calls from population-based sequencing of HIV-1 are a

marker for viral diversity and the age of infection. *Clin Infect Dis* 2011;52(4):532-9.

31. Kowalska JD, Mocroft A, Ledergerber B, Florence E, Ristola M, Begovac J, Sambatakou H, Pedersen C, Lundgren JD, Kirk O. A standardized algorithm for determining the underlying cause of death in HIV infection as AIDS or non-AIDS related: results from the EuroSIDA study. *HIV Clin Trials* 2011;12(2):109-17.
32. Kowalska JD, Reekie J, Mocroft A, Reiss P, Ledergerber B, Gatell J, Monforte AD, Phillips A, Lundgren JD, Kirk O. Long-term exposure to combination antiretroviral therapy and risk of death from specific causes: no evidence for any previously unidentified increased risk due to antiretroviral therapy. *AIDS* 2011. [Epub ahead of print]
33. Kuster SP, Katz KC, Blair J, Downey J, Drews SJ, Finkelstein S, Fowler R, Green K, Gubbay J, Hassan K, Lapinsky SE, Mazzulli T, McRitchie D, Pataki J, Plevneshi A, Powis J, Rose D, Sarabia A, Simone C, Simor A, McGeer A. When should a diagnosis of influenza be considered in adults requiring intensive care unit admission? Results of population-based active surveillance in Toronto. *Crit Care* 2011;15(4):R182.
34. Kuster SP, Shah PS, Coleman BL, Lam PP, Tong A, Wormsbecker A, McGeer A. Incidence of influenza in healthy adults and healthcare workers: a systematic review and meta-analysis. *PLoS One* 2011;6(10):e26239.
35. Kuster SP, Tuite AR, Kwong JC, McGeer A, Fisman DN. Evaluation of coseasonality of influenza and invasive pneumococcal disease: results from prospective surveillance. *PLoS Med* 2011;8(6):e1001042.
36. Ledergerber B, Cavassini M, Battegay M, Bernasconi E, Vernazza P, Hirschel B, Furrer H, Rickenbach M, Weber R. Trends over time of virological and immunological characteristics in the Swiss HIV Cohort Study. *HIV Med* 2011;12(5):279-88.
37. Li JZ, Paredes R, Ribaud HJ, Svarovskaia ES, Metzner KJ, Kozal MJ, Hullsiek KH, Balduin M, Jakobsen MR, Geretti AM, Thiebaut R, Ostergaard L, Masquelier B, Johnson JA, Miller MD, Kuritzkes DR. Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. *JAMA* 2011;305(13):1327-35.
38. Lubomirov R, Colombo S, di Iulio J, Ledergerber B, Martinez R, Cavassini M, Hirschel B, Bernasconi E, Elzi L, Vernazza P, Furrer H, Gunthard HF, Telenti A. Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study. *J Infect Dis* 2011;203(2):246-57.
39. Macheboeuf P, Buffalo C, Fu CY, Zinkernagel AS, Cole JN, Johnson JE, Nizet V, Ghosh P. Streptococcal M1 protein constructs a pathological host fibrinogen network. *Nature* 2011;472(7341):64-8.
40. Magenta L, Dell-Kuster S, Richter WO, Young J, Hasse B, Flepp M, Hirschel B, Vernazza P, Evison J, Cavassini M, Decosterd LA, Bucher HC, Bernasconi E. Lipid and lipoprotein profile in HIV-infected patients treated with

lopinavir/ritonavir as a component of the first combination antiretroviral therapy. *AIDS Res Hum Retroviruses* 2011;27(5):525-33.

41. Marzolini C, Back D, Weber R, Furrer H, Cavassini M, Calmy A, Vernazza P, Bernasconi E, Khoo S, Battegay M, Elzi L. Ageing with HIV: medication use and risk for potential drug-drug interactions. *J Antimicrob Chemother* 2011;66(9):2107-11.
42. Mayer D, Hasse B, Koelliker J,ENZLER M, Veith FJ, Rancic Z, Lachat M. Long-Term Results of Vascular Graft and Artery Preserving Treatment With Negative Pressure Wound Therapy in Szilagyi Grade III Infections Justify a Paradigm Shift. *Ann Surg* 2011;254(5):754-60.
43. Meier S, Weber R, Zbinden R, Ruef C, Hasse B. Extended-spectrum beta-lactamase-producing Gram-negative pathogens in community-acquired urinary tract infections: an increasing challenge for antimicrobial therapy. *Infection* 2011;39(4):333-40.
44. Metzner KJ, Leemann C, Di Giallonardo F, Grube C, Scherrer AU, Braun D, Kuster H, Weber R, Guenthard HF. Reappearance of minority K103N HIV-1 variants after interruption of ART initiated during primary HIV-1 infection. *PLoS One* 2011;6(7):e21734.
45. Metzner KJ, Rauch P, Braun P, Knechten H, Ehret R, Korn K, Kaiser R, Sichtig N, Ranneberg B, van Lunzen J, Walter H. Prevalence of key resistance mutations K65R, K103N, and M184V as minority HIV-1 variants in chronically HIV-1 infected, treatment-naïve patients. *J Clin Virol* 2011;50(2):156-61.
46. Miller RC, Schlaepfer E, Baenziger S, Cramer R, Zeller S, Byland R, Audige A, Nadal D, Speck RF. HIV interferes with SOCS-1 and -3 expression levels driving immune activation. *Eur J Immunol* 2011;41(4):1058-69.
47. Mugavero MJ, May M, Ribaldo HJ, Gulick RM, Riddler SA, Haubrich R, Napravnik S, Abgrall S, Phillips A, Harris R, Gill MJ, de Wolf F, Hogg R, Gunthard HF, Chene G, D'Arminio Monforte A, Guest JL, Smith C, Murillas J, Berenguer J, Wyen C, Domingo P, Kitahata MM, Sterne JA, Saag MS. Comparative effectiveness of initial antiretroviral therapy regimens: ACTG 5095 and 5142 clinical trials relative to ART-CC cohort study. *J Acquir Immune Defic Syndr* 2011;58(3):253-60.
48. Murray M, Hogg R, Lima V, May M, Moore D, Abgrall S, Bruyand M, D'Arminio Monforte A, Tural C, Gill M, Harris R, Reiss P, Justice A, Kirk O, Saag M, Smith C, Weber R, Rockstroh J, Khaykin P, Sterne J. The effect of injecting drug use history on disease progression and death among HIV-positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis. *HIV Med* 2011. [Epub ahead of print]
49. Ortiz M, Poloni ES, Furrer H, Kovari H, Martinez R, Arnedo M, Elzi L, Bernasconi E, Vernazza P, Hirschel B, Cavassini M, Ledergerber B, Gunthard HF, Telenti A, Tarr PE. No longitudinal mitochondrial DNA sequence changes in HIV-infected individuals with and without lipodystrophy. *J Infect Dis* 2011;203(5):620-4.

50. Petoumenos K, Worm S, Reiss P, de Wit S, d'Arminio Monforte A, Sabin C, Friis-Moller N, Weber R, Mercie P, Pradier C, El-Sadr W, Kirk O, Lundgren J, Law M. Rates of cardiovascular disease following smoking cessation in patients with HIV infection: results from the D:A:D study(\*). *HIV Med* 2011;12(7):412-21.
51. Quiblier C, Zinkernagel AS, Schuepbach RA, Berger-Bachi B, Senn MM. Contribution of SecDF to *Staphylococcus aureus* resistance and expression of virulence factors. *BMC Microbiol* 2011;11:72.
52. Rampini SK, Bloemberg GV, Keller PM, Buchler AC, Dollenmaier G, Speck RF, Bottger EC. Broad-Range 16S rRNA Gene Polymerase Chain Reaction for Diagnosis of Culture- Negative Bacterial Infections. *Clin Infect Dis* 2011;53(12):1245-51.
53. Reekie J, Reiss P, Ledergerber B, Sedlacek D, Parczewski M, Gatell J, Katlama C, Fatkenheuer G, Lundgren JD, Mocroft A. A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study. *HIV Med* 2011;12(5):259-68.
54. Rieder P, Joos B, Scherrer AU, Kuster H, Braun D, Grube C, Niederost B, Leemann C, Gianella S, Metzner KJ, Boni J, Weber R, Gunthard HF. Characterization of Human Immunodeficiency Virus Type 1 (HIV-1) Diversity and Tropism in 145 Patients With Primary HIV-1 Infection. *Clin Infect Dis* 2011;53(12):1271-9.
55. Rotger M, Dalmau J, Rauch A, McLaren P, Bosinger SE, Martinez R, Sandler NG, Roque A, Liebner J, Battegay M, Bernasconi E, Descombes P, Erkizia I, Fellay J, Hirschel B, Miro JM, Palou E, Hoffmann M, Massanella M, Blanco J, Woods M, Gunthard HF, de Bakker P, Douek DC, Silvestri G, Martinez-Picado J, Telenti A. Comparative transcriptomics of extreme phenotypes of human HIV-1 infection and SIV infection in sooty mangabey and rhesus macaque. *J Clin Invest* 2011;121(6):2391-400.
56. Roysland K, Gran JM, Ledergerber B, von Wyl V, Young J, Aalen OO. Analyzing direct and indirect effects of treatment using dynamic path analysis applied to data from the Swiss HIV Cohort Study. *Stat Med* 2011;30(24):2947-58.
57. Ruprecht CR, Krarup A, Reynell L, Mann AM, Brandenburg OF, Berlinger L, Abela IA, Regoes RR, Gunthard HF, Rusert P, Trkola A. MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1. *J Exp Med* 2011;208(3):439-54.
58. Rusert P, Krarup A, Magnus C, Brandenburg OF, Weber J, Ehlert AK, Regoes RR, Gunthard HF, Trkola A. Interaction of the gp120 V1V2 loop with a neighboring gp120 unit shields the HIV envelope trimer against cross-neutralizing antibodies. *J Exp Med* 2011;208(7):1419-33.
59. Sax H, Uckay I, Balmelli C, Bernasconi E, Boubaker K, Muhlemann K, Ruef C, Troillet N, Widmer A, Zanetti G, Pittet D. Overall burden of healthcare-associated infections among surgical patients. Results of a national study. *Ann Surg* 2011;253(2):365-70.

60. Scherrer AU, Ledergerber B, von Wyl V, Boni J, Yerly S, Klimkait T, Burgisser P, Rauch A, Hirschel B, Cavassini M, Elzi L, Vernazza PL, Bernasconi E, Held L, Gunthard HF. Improved Virological Outcome in White Patients Infected With HIV-1 Non-B Subtypes Compared to Subtype B. *Clin Infect Dis* 2011;53(11):1143-1152.
61. Scherrer AU, von Wyl V, Boni J, Yerly S, Klimkait T, Burgisser P, Garzoni C, Hirschel B, Cavassini M, Battegay M, Vernazza PL, Bernasconi E, Ledergerber B, Gunthard HF. Viral suppression rates in salvage treatment with raltegravir improved with the administration of genotypic partially active or inactive nucleoside/tide reverse transcriptase inhibitors. *J Acquir Immune Defic Syndr* 2011;57(1):24-31.
62. Scherrer AU, von Wyl V, Gotte M, Klimkait T, Cellera C, Yerly S, Boni J, Held L, Ledergerber B, Gunthard HF. Polymorphic mutations associated with the emergence of the multi-nucleoside/tide resistance mutations 69 insertion and Q151M. *J Acquir Immune Defic Syndr* 2011. [Epub ahead of print]
63. Scherrer AU, von Wyl V, Joos B, Klimkait T, Burgisser P, Yerly S, Boni J, Ledergerber B, Gunthard HF. Predictors for the emergence of the 2 multi-nucleoside/nucleotide resistance mutations 69 insertion and Q151M and their impact on clinical outcome in the Swiss HIV cohort study. *J Infect Dis* 2011;203(6):791-7.
64. Schlaepfer E, Speck RF. TLR8 activates HIV from latently infected cells of myeloidmonocytic origin directly via the MAPK pathway and from latently infected CD4+ T cells indirectly via TNF-alpha. *J Immunol* 2011;186(7):4314-24.
65. Schöni-Affolter F, Keiser O, Mwango A, Stringer J, Ledergerber B, Mulenga L, Bucher HC, Westfall AO, Calmy A, Boule A, Chintu N, Egger M, Chi BH. Estimating loss to follow-up in HIV-infected patients on antiretroviral therapy: the effect of the competing risk of death in Zambia and Switzerland. *PLoS One* 2011;6(12):e27919.
66. Schuepbach J, Bisset LR, Regenass S, Burgisser P, Gorgievski M, Steffen I, Andreutti C, Martinetti G, Shah C, Yerly S, Klimkait T, Gebhardt M, Schöni-Affolter F, Rickenbach M. and the Swiss HIV Cohort Study. High specificity of line-immunoassay based algorithms for recent HIV-1 infection independent of viral subtype and stage of disease. *BMC Infect Dis* 2011;11:254.
67. Sendi P, Christensson B, Uckay I, Trampuz A, Achermann Y, Boggian K, Svensson D, Widerstrom M, Zimmerli W. Group B streptococcus in prosthetic hip and knee jointassociated infections. *J Hosp Infect* 2011;79(1):64-9.
68. Soriano V, Arasteh K, Migrone H, Lutz T, Opravil M, Andrade-Villanueva J, Antunes F, Di Perri G, Podzamczar D, Taylor S, Domingo P, Gellermann H, de Rossi L. Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial. *Antivir Ther* 2011;16(3):339-48.
69. Stadler T, Kouyos R, von Wyl V, Yerly S, Boni J, Burgisser P, Klimkait T, Joos B, Rieder P, Xie D, Gunthard HF, Drummond AJ, Bonhoeffer S. Estimating the

Basic Reproductive Number from Viral Sequence Data. *Mol Biol Evol* 2011. [Epub ahead of print]

70. Staehelin C, Keiser O, Calmy A, Weber R, Elzi L, Cavassini M, Schmid P, Bernasconi E, Furrer H. Longer term clinical and virological outcome of Sub-Saharan African participants on antiretroviral treatment in the Swiss HIV Cohort Study. *J Acquir Immune Defic Syndr* 2012. [Epub ahead of print]
71. Taegtmeyer AB, Muller V, Kovari H, Kullak-Ublick GA, Corti N. Effect of continuous venovenous hemodiafiltration on darunavir and raltegravir exposure after administration via a gastroduodenal tube. *AIDS* 2011;25(10):1339-41.
72. Teuffel O, Kuster SP, Hunger SP, Conter V, Hitzler J, Ethier MC, Shah PS, Beyene J, Sung L. Dexamethasone versus prednisone for induction therapy in childhood acute lymphoblastic leukemia: a systematic review and meta-analysis. *Leukemia* 2011;25(8):1232-8.
73. Thierfelder C, Weber R, Elzi L, Furrer H, Cavassini M, Calmy A, Bernasconi E, Gutmann C, Ledergerber B. Participation, characteristics and retention rates of HIV-positive immigrants in the Swiss HIV Cohort Study(\*). *HIV Med* 2011. [Epub ahead of print]
74. von Wyl V, Gianella S, Fischer M, Niederoest B, Kuster H, Battegay M, Bernasconi E, Cavassini M, Rauch A, Hirschel B, Vernazza P, Weber R, Joos B, Gunthard HF. Early Antiretroviral Therapy During Primary HIV-1 Infection Results in a Transient Reduction of the Viral Setpoint upon Treatment Interruption. *PLoS One* 2011;6(11):e27463.
75. von Wyl V, Kouyos RD, Yerly S, Boni J, Shah C, Burgisser P, Klimkait T, Weber R, Hirschel B, Cavassini M, Staehelin C, Battegay M, Vernazza PL, Bernasconi E, Ledergerber B, Bonhoeffer S, Gunthard HF. The role of migration and domestic transmission in the spread of HIV-1 non-B subtypes in Switzerland. *J Infect Dis* 2011;204(7):1095-103.
76. von Wyl V, Yerly S, Boni J, Shah C, Cellerai C, Klimkait T, Battegay M, Bernasconi E, Cavassini M, Furrer H, Hirschel B, Vernazza PL, Ledergerber B, Gunthard HF. Incidence of HIV-1 Drug Resistance Among Antiretroviral Treatment-Naive Individuals Starting Modern Therapy Combinations. *Clin Infect Dis* 2012. [Epub ahead of print]
77. Wandeler G, Keiser O, Hirschel B, Gunthard HF, Bernasconi E, Battegay M, Clerc O, Vernazza PL, Furrer H. A Comparison of Initial Antiretroviral Therapy in the Swiss HIV Cohort Study and the Recommendations of the International AIDS Society-USA. *PLoS One* 2011;6(12):e27903.
78. Wittkop L, Gunthard HF, de Wolf F, Dunn D, Cozzi-Lepri A, de Luca A, Kucherer C, Obel N, von Wyl V, Masquelier B, Stephan C, Torti C, Antinori A, Garcia F, Judd A, Porter K, Thiebaut R, Castro H, van Sighem AI, Colin C, Kjaer J, Lundgren JD, Paredes R, Pozniak A, Clotet B, Phillips A, Pillay D, Chene G. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN



joint project): a European multicohort study. *Lancet Infect Dis* 2011;11(5):363-71.

79. Young J, Klein MB, Ledergerber B. Noncirrhotic portal hypertension and didanosine: a reanalysis. *Clin Infect Dis* 2011;52(1):154-5.
80. Young J, Scherrer AU, Gunthard HF, Opravil M, Yerly S, Boni J, Rickenbach M, Fux CA, Cavassini M, Bernasconi E, Vernazza P, Hirschel B, Battegay M, Bucher HC. Efficacy, tolerability and risk factors for virological failure of darunavir-based therapy for treatment-experienced HIV-infected patients: the Swiss HIV Cohort Study. *HIV Med* 2011;12(5):299-307.
81. Zinkernagel AS, Hruz P, Uchiyama S, von Kockritz-Blickwede M, Schuepbach RA, Hayashi T, Carson DA, Nizet V. Importance of Toll-Like Receptor 9 in Host Defense against M1T1 Group A Streptococcus Infections. *J Innate Immun* 2011. [Epub ahead of print]

### **Buchkapitel**

1. Müller, N.J. Part II Specific Pathogens: Pneumocystis jirovecii Pneumonia: Prophylaxis and Therapy. In: *The AST handbook of transplant infections*. Kumar, D; Humar, A. (eds.) p 79, Wiley-Blackwell, London, 2011
2. Müller N.J. and Fishman J.A. Infections in the Organ Transplant Recipient. In: *Medical Care of the Liver Transplant Patient*. 4th Edition. Clavien P.A., Trotter J.F. (eds). Wiley-Blackwell, London, 2011 [Epub ahead of print].
3. Weber R, Deplazes P, Mathis A. Microsporidia, p. 2190-99. In: Murray PR, et al. (eds.) *Manual of Clinical Microbiology*. American Society for Microbiology, 10th Edition, ASM Press, Washington D.C., 2011.

### **Case Reports**

1. Bansal V, Metzner KJ, Niederost B, Leemann C, Boni J, Gunthard HF, Fehr JS. Minority K65R variants and early failure of antiretroviral therapy in HIV-1-infected Eritrean Immigrant. *Emerg Infect Dis* 2011;17(10):1966-8.
2. Gaudenz R, Sailer S, Widmer GM, Kestenholz P, Müller N. Eine Grippe mit Folgen. *Schweiz. Med Forum* 2011;11(39):681-683.
3. Kocher C, Weber R, Friedl A. A case study of female genital tuberculosis in a Western European setting. *Infection* 2011;39(1):59-63.
4. Krones T, Rüegg CA, Günthard HF, Rid A, Wild V. Kommentar I zum Fall: Heimlicher Transfer von HIV-Medikamenten nach Afrika. *Ethik Med*. 2011 [Epub ahead of print]
5. Lederer H, Achermann Y, Tinguely M, Stenner F, Fehr J. Multicentric Castleman's disease as a cause for unclear febrile episodes in a 55-year-old HIV-infected man. *Infection* 2011. [Epub ahead of print]
6. Preiswerk B, Allemann IB, Maggiorini M, Müller V. From a pimple to a crater. *Lancet* 2011;378(9791):636.

7. Preiswerk B, Ullrich S, Speich R, Bloemberg GV, Hombach M. Human infection with *Delftia tsuruhatensis* isolated from a central venous catheter. *J Med Microbiol* 2011;60(Pt 2):246-8.

### **Übersichtsartikel /Reviews**

1. Kovari H, Weber R. Influence of antiretroviral therapy on liver disease. *Curr Opin HIV AIDS* 2011;6(4):272-7.
2. Metzner KJ. [Evolution and Diversity of HIV-1]. *Praxis (Bern 1994)* 2011;100(1):29-35.
3. Mueller NJ, Takeuchi Y, Mattiuzzo G, Scobie L. Microbial safety in xenotransplantation. *Curr Opin Organ Transplant* 2011;16(2):201-6.

### **Editorials**

1. Ruef C. Antibiotic resistance really starts to hurt. *Infection* 2011;39(6):499-500.
2. Ruef C. Community-onset bacteremia may be an ominous sign. *Infection* 2011;39(5):397.
3. Ruef C. Why do physicians prescribe antibiotics? *Infection* 2011;39(4):287.
4. Ruef C. Prolonged duration of surgery: a new look at the causes. *Infection* 2011;39(3):183-4.
5. Ruef C. *Borrelia burgdorferi* bacteremia. *Infection* 2011;39(1):1.

### **Andere Arbeiten**

1. Johnson VA, Calvez V, Gunthard HF, Paredes R, Pillay D, Shafer R, Wensing AM, Richman DD. 2011 update of the drug resistance mutations in HIV-1. *Top Antivir Med* 2011;19(4):156-164.
2. Wagner C, Preiswerk B, Weber R. Disseminated Kaposi sarcoma in newly diagnosed HIV. *Infection* 2011;39(1):91.
3. Wagner C, Cortesi C, Kocher C, Kunz I, Schwarz U. Knöpfe im Gehirn. *Swiss Medical Forum/Schweizerisches Medizin-Forum*, 2011; 11 (11) 201.

### **Habilitationen**

1. Zinkernagel A. Neue Therapieansätze für Bakterielle Infektionen. Habilitation an der Universität Zürich, 2011.

### **Dissertationen**

1. Althaus C. Interplay between HIV-1 transcription and the pathways of intracellular innate defense. Dissertation an der Universität Zürich, 2011.

2. Giner A. Primäres Management und Outcome von Patienten und Patientinnen mit Pneumokokkenbakteriämie am Universitätsspital Zürich, Dissertation an der Universität Zürich, 2011.
3. Mekker A. An Example of Collateral Damage: Cytomegalovirus Infection and Immune Senescence. Dissertation an der Universität Zürich, 2011
4. Nicoletti J. Risikofaktoren, Behandlung und Verlauf von Infektionen mit Ciprofloxacin resistenten Escherichia coli an der Urologischen Klinik des Universitätsspitals Zürich. Dissertation an der Universität Zürich, 2011.
5. Rieder Ph. Primary HIV-1 infection in Zurich : molecular studies of transmission biology and epidemiology. Dissertation an der Universität Zürich, 2011.
6. Ruppik M. Todesursachen bei HIV-Infizierten der Schweizerischen HIV-Kohortenstudie im Zeitraum 2005 – 2009. Dissertation an der Universität Zürich, 2011.
7. Scherrer A. Emergence, mechanisms and clinical relevance of HIV-1 drug resistance in the era of combination antiretroviral therapy. Dissertation an der Universität Zürich, 2011

### **Masterarbeiten**

1. Hofmänner D. Nodular regenerative hyperplasia of the liver associated with didanosine persists for years even after its interruption. Masterarbeit an der Universität Zürich, 2011.